These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 15201598)

  • 21. Tumor necrosis factor inhibitors in psoriatic arthritis.
    Mantravadi S; Ogdie A; Kraft WK
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.
    Lories RJ; de Vlam K
    Expert Opin Biol Ther; 2014 Dec; 14(12):1825-36. PubMed ID: 25366335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
    [No Abstract]   [Full Text] [Related]  

  • 24. New drugs for peripheral joint psoriatic arthritis.
    Drug Ther Bull; 2006 Jan; 44(1):1-5. PubMed ID: 16425898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriatic arthritis: a guide for dermatology nurses.
    Gottlieb AB
    Dermatol Nurs; 2003 Apr; 15(2):107-10, 113-8; quiz 119. PubMed ID: 12751345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
    Coates LC; Tillett W; Chandler D; Helliwell PS; Korendowych E; Kyle S; McInnes IB; Oliver S; Ormerod A; Smith C; Symmons D; Waldron N; McHugh NJ;
    Rheumatology (Oxford); 2013 Oct; 52(10):1754-7. PubMed ID: 23887065
    [No Abstract]   [Full Text] [Related]  

  • 28. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
    Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
    Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
    Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psoriatic arthritis.
    Wollina U; Unger L; Heinig B; Kittner T
    Dermatol Ther; 2010; 23(2):123-36. PubMed ID: 20415819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and management of psoriatic arthritis.
    Balakrishnan C; Madnani N
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psoriatic arthritis treatment: biological response modifiers.
    Mease PJ; Antoni CE
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii78-82. PubMed ID: 15708944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
    Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
    J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Arthritis psoriatica].
    de Rie MA; van Kuijk AW; Goedkoop AY; Tak PP
    Ned Tijdschr Geneeskd; 2007 Aug; 151(31):1716-22. PubMed ID: 17784693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.